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PCV14
USING THE GENERAL PRACTICE RESEARCH 
DATABASE TO GENERATE AN “AT RISK 
REGISTER” FOR A PRIMARY CARE STROKE 
PREVENTION PROGRAM
Chapman SR, Heatlie HF, Frischer M, Bashford J
Department of Medicines Management, Keele University, 
Staffordshire, UK
OBJECTIVE: To create a register of patients in the West
Midlands from the General Practice Research Database
(GPRD) who may be eligible for primary prevention
treatment of stroke with an ACE inhibitor according to
the inclusion and exclusion criteria of the HOPE study
METHODS: A retrospective database analysis for pa-
tients registered on GPRD during 1998 THE GPRD is a
representative sample of approximately 5% of the popu-
lation. Participating general practitioners enter all pre-
scriptions, significant morbidity and consultation out-
comes. Patients over 54 at January 1998 were selected,
then those at high risk of cardiovascular events according
to the HOPE study diagnostic inclusion criteria. Patients
were categorized as either treated or not treated. Treated
patients were further classified as either having received
an ‘ACE inhibitor’ or ‘other antihypertensive’ treatment.
Patients receiving an ACE inhibitor prescriptions as well
as ‘other antihypertensive’ treatment were classified as
ACE inhibitor patients. ACE inhibitor patients were then
sub-classified into higher and lower dose ACE inhibitors.
Higher dose ACE treatment was defined as patients pre-
scribed ACE inhibitors at or greater than the World
Health Organization (WHO) defined daily dose (DDD).
Counts were made for patients receiving ramipril as op-
posed to another ACE inhibitor. RESULTS: The GPRD
had 214,401 patients registered during 1998. 66,548 pa-
tients were over 54 years old, 10,983 (16.5%) were clas-
sified as at risk of cardiovascular events. 3,635 (33%) at
risk patients were untreated. 7,348 patients were treated;
of whom 2,156 were receiving some form of ACE inhibi-
tor therapy. 1,700 patients were on high dose ACE inhib-
itor therapy, of which 284 had been prescribed ramipril.
CONCLUSION: THE GPRD can be used to create a reg-
ister of at risk patients in primary care. This gives a mea-
sure of potential workload, and could populate a phar-
macoeconomic study on the cost of implementing the
HOPE recommendations.
PCV15
ANTI-HYPERTENSIVE AGENTS AND THE
RISK OF HIP OR WRIST FRACTURES IN
AN OTHERWISE HEALTHY
COMMUNITY POPULATION
Läer C, LeLorier J
Centre de Recherche, Hôtel-Dieu du Centre hospitalier de 
l’Université de Montréal, Montréal, QC, Canada
OBJECTIVE: Psychotropic agents are an established risk
factor for hip fractures. These agents induce drowsiness,
sleepiness, and orthostatic hypotension. Orthostatic hy-
potension is a major side effect of anti-hypertensive agents
(AH). Conflicting results have been published with respect
to AH-agents and the risk of hip fractures, with relative
risk estimates ranging from 0.46 (CI 95%: 0.13–1.55) to
11.8 (CI 95%: 6.11–22.69). The objective is to assess the
risk of hip or wrist fractures in an otherwise healthy hy-
pertensive elderly community population. METHOD: A
nested case-control study of AH-users older than 65
years at the first dispensation of an AH (excluding ni-
trates and high dose furosemide) was conducted on a
10% random sample from January 1st 1987 to Decem-
ber 31st 1994, and a 20% sample of all AH-users
between August 1st 1992 and August 30th 1997 of
the “Régie de l’assurance maladie du Québec” database
(RAMQ). Community cases and controls were selected at
their first hospitalized index event. Both groups had
taken AH-medication and only one antibiotic for a maxi-
mum of 14 days in the 92 days preceding the index day.
Cases were subjects with hip or wrist fractures, and con-
trols had pneumonia, cellulitis, diverticulitis, pyelone-
phritis or acute appendicitis. Conditional logistic regres-
sion was performed. RESULTS: From our AH-cohort of
160,940 members, 254 cases and 897 controls were se-
lected. The overall adjusted odds-ratio was 0.87 (CI 95%:
0.66–1.17). CONCLUSION: Modern anti-hypertensive
therapy does not increase the risk of fractures of the hip
or wrist in an otherwise healthy elderly community popu-
lation.
PCV16
COST-EFFECTIVENESS OF
LOW-MOLECULAR WEIGHT HEPARIN
VERSUS ORAL ANTICOAGULANTS FOR 
SECONDARY PROPHYLAXIS OF
VENOUS THROMBOEMBOLISM
Marchetti M1, Pistorio A2, Barosi G1
1Laboratory of Medical Informatics, IRCCS Policlinico S.Matteo, 
Pavia, Italy; 2Epidemiology Center IRCCS Policlinico S.Matteo, 
Pavia, Italy
OBJECTIVE: Recent evidence suggests that low molecu-
lar weight heparin (LMWH) can be used as an alternative
to oral anticoagulants in the prevention of recurrences af-
ter deep venous thrombosis (DVT). Our objective was to
examine the clinical, economic and policy implications of
LMWH instead of oral anticoagulants as secondary pro-
phylaxis for DVT. METHODS: Fixed-effect model was
used to conduct a meta-analysis of data about safety and
effectiveness of LMWH from 4 trials. A decision tree was
constructed using published data to simulate the out-
comes and cost of care of patients receiving secondary
prophylaxis with either LMWH or oral anticoagulants
after a first episode of DVT. RESULTS: Meta-analysis
showed that the OR for bleeding, DVT and pulmonary
embolism were respectively 0.402 (0.153–1.057), 0.665
(0.22–2.013) and 0.462 (0.075–2.825). None of the three
OR was significant, however, the upper limit of the 95%
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confidence interval around the estimate for bleeding was
near to 1. When a cohort of 1,000 simulated patients
with DVT received secondary prophylaxis with LMWH
instead of warfarin 4.5 lives were saved, i.e. 22 addi-
tional days of life and 18 additional quality-adjusted
days. Prophylaxis with LMWH cost $768 more than
prophylaxis with warfarin, which is $15,360 per QALY
saved. The results were sensible to the efficacy of LMWH
in reducing pulmonary embolism: LMWH is no longer
effective if patients incur 35% more episodes of pulmo-
nary embolism than with warfarin. CONCLUSIONS:
LMWH is a cost-effective drug to perform secondary
prophylaxis after a thromboembolic episode. However,
some critical issues need to be definitively ascertained be-
fore recommending it: first, the neat preventive efficacy
of LMWH over warfarin need to be assessed by larger
trials; second, patient preferences for oral or subcutane-
ous administrations are to be elicited.
PCV17
VARIABILITY IN ABCIXIMAB (REOPRO®) USAGE: 
EVIDENCE-BASED OR BUDGET-DRIVEN?
Zwart-van Rijkom J1,2, Leufkens H1, Broekmans A1
1Department of Pharmaco-epidemiology & Pharmaco-therapy, 
Utrecht University, Utrecht, The Netherlands; 2Institute for 
Medical Technology Assessment, Erasmus University, 
Rotterdam, The Netherlands
OBJECTIVE: To study the patterns of prescribing of abcix-
imab, a platelet function inhibitor, in percutaneous translu-
minal coronary angioplasty (PTCA) centres and to identify
which factors determine the level of usage per centre.
METHODS: The opinion-leading cardiologists from all 13
PTCA centres in the Netherlands have co-operated in our
research. The questions about the use of abciximab in 1998
concerned indications, number of PTCAs performed, num-
ber of patients treated with abciximab, the funding and
possible financial restrictions on the treatment, participa-
tion in clinical trials in the past, the proportion of patients
receiving stents, and opinion on the appropriate level of ab-
ciximab usage. RESULTS: The level of abciximab usage
varies markedly between centres, ranging from 2% to 36%
of all PTCA procedures. Three out of four abciximab pre-
scriptions surround stenting procedures. The indications
for prescribing abciximab significantly differed between
centres. Many physicians use abciximab not only to pre-
vent thrombotic complications, but also to treat acute com-
plications when they occur during PTCA and in case of
suboptimal results. Together: budget, investigatorship, size,
and type of the institution are highly predictive for the level
of abciximab usage (R2  0.96, P  0.001). The more pa-
tients doctors have included in clinical trials in the past, the
higher the likelihood they prescribe abciximab. CONCLU-
SIONS: Shortly after its introduction, patterns of abcix-
imab prescribing varied significantly between PTCA cen-
tres. Abciximab is not only administered preventively, but
also during and after the procedure, even though this strat-
egy has never been evaluated in controlled trials. Budget
and involvement in clinical trials in the past were important
predictors of the level of usage in each centre. This is not a
desirable situation, since it indicates that the level of pre-
scribing is not so much based on patient mix, but is largely
explained by non-medical factors.
PCV18
COST-EFFECTIVENESS OF PREVENTION OF 
ATHEROTHROMBOTIC DISEASE WITH ASPIRIN 
VERSUS CLOPIDOGREL IN GREECE
Geitona M1, Kyriopoulos J1, Geitonas C2, Papademetriou A3, 
Nikolaou V4
1Department of Health Economics, National School of Public 
Health, Athens, Greece; 2Deptartment of Economics, 
University of Warwick, Coventry, UK; 3Deptartment of 
Neurology, Red Cross General Hospital, Athens, Greece; 
4Department of Cardiology, Red Cross General Hospital, 
Athens, Greece
OBJECTIVE: Given that secondary prevention of athero-
thrombotic disease with antiplatelets drugs is widely es-
tablished in our country, in the present paper an attempt
is made to compare the cost and effectiveness of 325 mg
aspirin versus 75 mg clopidogrel once daily. METHODS:
A decision analysis model was developed based on epide-
miological and clinical data, the effectiveness ratios, the
health care resource utilization and unit cost. It was as-
sumed that the effects of clopidogrel in Greek patients
would be the same as those of the CAPRIE study (1996).
Direct and indirect cost was estimated. Patients hospital-
ized for ischaemic, cerebrovascular and peripheral artery
disease were selected for evaluation. Clinical, demographic
and economic data derive from the National Statistical
Office of Greece and the Ministry of Labour and Social
Security. Effectiveness is expressed in years of life saved
and all results are calculated on 1 year of treatment. RE-
SULTS: Total cost for patients suffering from athero-
thrombotic disease in 1998 in Greece, is estimated at
$1,05 billion, while 44.5% concerns the indirect cost.
The incremental cost per year of life saved is $16,717 per
patient suffering from ischaemic and peripheral disease
(moderate events) and $3,217 per severe event. Addition-
ally, the incremental cost per year of life saved for patients
with cerebrovascular disease is estimated at $13,717 per
moderate event and $1,550 per severe event without dis-
counting. The administration of clopidogrel compared
with aspirin yields an annual gain of 257 years of life to
working force patients and a net annual societal benefit
that ranges from $6 to $10 million. Sensitivity analysis
showed that outcomes are sensitive to price differences
between the two drugs and the severity of illness.
CONCLUSION: Our analysis showed that clopidogrel
treatment is cost-effective, especially in severe events.
Economic evaluation results should be incorporated in
the decision-making of the health care sector in Greece.
